RxDoctor Payments DataLook up a doctor →

Eva Tsalikian

Pediatric Endocrinology · Iowa City, IANPI 1619963949

Payments from drug & device makers

$957,159in general payments, 2019–2025

Across 603 payments — averaging $1587.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$304K
  • Takeda Pharmaceuticals U.S.A., Inc.$170K
  • Novo Nordisk AS$130K
  • OPKO Pharmaceuticals, LLC$93K
  • Abbott$64K
  • Astrazeneca UK Limited$58K
  • plus $138K from 9 others

What the payments were for

  • Consulting fees$10043%
  • Food & beverage$3314%
  • Education$9742%

General payments by program year

20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim12$304,413
Takeda Pharmaceuticals U.S.A., Inc.31$169,977
Novo Nordisk AS499$129,897
OPKO Pharmaceuticals, LLC6$93,104
Abbott4$64,106
Astrazeneca UK Limited6$57,500
Boehringer Ingelheim Pharma GmbH & Co.kg13$44,033
Ascendis Pharma Endocrinology Inc7$32,575
Amgen1$27,310
Regeneron5$26,013
Boehringer Ingelheim France S.a.s.12$4,415
Merck2$3,586
Pfizer1$100
Novo Nordisk3$97
Biomarin Pharmaceutical Inc.1$33

How this compares

Too few pediatric endocrinology providers in Iowato place this figure against a meaningful peer group, so we don't.

Other pediatric endocrinology in Iowa City

See the full list for Iowa →

Where these figures come from

Is this you, or does something look wrong? →